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Following the rapid increase of infections due to 
carbapenemase-producing Enterobacteriaceae (CPE) 
in Italy, the national surveillance of bloodstream 
infections (BSI) due to CPE (Klebsiella pneumo-
niae  and  Escherichia coli) was instituted in 2013. All 
CPE-BSI cases reported to the surveillance in the years 
2014–17 were analysed in order to investigate inci-
dence rate (IR), trend, main individual characteristics 
and enzymes involved in CPE resistance. Throughout 
this period, 7,632 CPE-BSI cases (IR: 3.14/100,000 
inhabitants) were reported from all 21 regions and 
autonomous provinces in Italy, with an increasing num-
ber of reported cases (2014: 1,403; 2015: 1,838; 2016: 
2,183; 2017: 2,208). CPE-BSI cases mainly occurred 
in subjects aged over 60 years (70.9%) and more fre-
quently in males (62.7%) than in females. Most of the 
cases originated in hospitals (87.2%), mainly in inten-
sive care units (38.0%), and were associated with 
central or peripheral venous catheter use (23.9%) or 
with urinary tract infections (21.1%). Almost all CPE-
BSI (98.1%) were due to K. pneumoniae carrying the K. 
pneumoniae  carbapenemase (KPC) enzyme (95.2%). 
These data show that carbapenemase-producing  K. 
pneumoniae  are endemic in our country, causing 
a high number of BSI and representing a threat to 
patient safety.
Introduction
The increase in carbapenem resistance in 
Enterobacteriaceae through carbapenemase enzyme 
production has been reported worldwide [1-6]. 
Carbapenemase-producing Enterobacteriaceae (CPE) 
infections are difficult to treat since CPE are resist-
ant to virtually all beta-lactam antibiotics and often 
contain additional mechanisms of resistance against 
second-line antibiotics such as aminoglycoside and 
fluoroquinolones. Recent studies have also shown 
emerging resistance to antibiotics of last resort (i.e. 
tigecycline or colistin), leaving very few therapeutic 
options [7-9]. According to the new taxonomy [10], 
carbapenem resistance is present not only in the fam-
ily Enterobacteriaceae sensu stricto but also in the 
other families now belonging in the Enterobacterales 
order. When compared with carbapenem-suscepti-
ble infections, those due to carbapenem-resistant 
Enterobacterales (CRE) show higher mortality rates, 
especially for bloodstream infections (BSI) [11,12]. 
Resistance to carbapenems impacts considerably 
on healthcare costs and loss of productivity [13]. In 
England, the overall cost of an outbreak due to CPE 
involving 40 patients in five hospitals was estimated 
at ca EUR 1.1 million over a 10-month period between 
March and December 2015 [14]. The high occurrence of 
cases, dearth of alternative drugs, high mortality and 
economic burden make CPE infections an important 
threat to public health worldwide.
Data obtained from the European Survey on 
Carbapenemase-Producing Enterobacteriaceae 
(EuSCAPE) project showed low frequencies of CRE in 
many European countries. On average, 1.3 patients per 
10,000 hospital admissions have carbapenemase-pro-
ducing Klebsiella pneumoniae or Eschericia coli isolated 
from a clinical specimen [15]. Italy experienced a rapid 
increase of infections due to CRE and to CPE, mostly 
caused by K. pneumoniae. Data from the Italian surveil-
lance of antibiotic resistance at the Istituto Superiore 
di Sanità (AR-ISS), based on a sample of hospital 
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laboratories reporting to the European Antimicrobial 
Resistance network (EARS-Net), showed that in 2009 
the percentage of carbapenem-resistant  K. pneumo-
niae  causing BSI was 1.3%; this percentage increased 
dramatically to 15.2% in 2010, to 26.7% in 2011 and 
to 34.3% in 2013, making K. pneumoniae  the principal 
antibiotic-resistance threat in Italy [15-18]. Most other 
European Union (EU)/European Economic Area (EEA) 
countries do not have the endemic levels seen in Italy: 
the EU/EEA population-weighted mean of  K. pneumo-
niae  resistant to carbapenems was 4.6% in 2010 and 
6.1% in 2016. In 2010, the percentage of carbapenem-
resistant  K. pneumoniae  was very high only in Greece 
(59.5%) and Cyprus (17.9%), where it remains at high 
levels. Romania has also reported an endemic situation 
for CRE since 2012 [18].
To monitor and improve the prevention and control of 
these infections, in February 2013 the Italian Ministry 
of Health (MoH) instituted national surveillance for 
CPE through a circular letter (MoH DGPRE n°4968 
26/02/2013), asking the 19 regional and the two pro-
vincial health authorities to report all cases of BSI due 
to carbapenem-resistant/-intermediate and/or carbap-
enemase-producing  K. pneumoniae  or  E. coli. Other 
Enterobacteriaceae were not included in the surveil-
lance, since these represent a small portion of all CPE 
in Italy [19].
In this paper, we report the results of this surveillance 
for the period from 2014 to 2017.
Methods
Case definition and diagnostic criteria for 
bloodstream infections due to carbapenemase-
producing Enterobacteriaceae
All BSI due to K. pneumoniae or E. coli with at least one 
of the following characteristics: (i) non-susceptibility 
(i.e. resistant or intermediate) to the carbapenem anti-
biotics imipenem and/or meropenem obtained by a 
routine antibiotic susceptibility method; and (ii) pro-
duction of carbapenemase identified by a phenotypic 
method [20] or by the detection of a carbapenemase 
gene by PCR or another molecular method.
In this case definition it was assumed that susceptibility 
to imipenem or meropenem is mainly due to the produc-
tion of carbapenemases. In fact, for Enterobacteriaceae 
isolates obtained in Italy and, in particular, for K. pneu-
moniae, this is by far the most prevalent mechanism of 
carbapenem resistance [15,16,21].
Information to be reported and data flow
Since April 2013, Local Health Units (LHUs) and hos-
pitals have had to report all cases of BSI due to CPE 
(CPE-BSI), according to the previous definition, to the 
regional health authorities, to the MoH and to the 
Istituto Superiore di Sanità (ISS) within 7 days from the 
date of diagnosis, using a paper form [22]. This form 
has two sections: the first contains personal data used 
for infection control purpose and the second contains 
information about the notifier (the name and the city 
of the hospital or LHU and the municipality where hos-
pital/LHU is located); patient demographics (sex, age 
at diagnosis, province of residence and nationality); 
patient location at onset of symptoms (hospital, other 
residential health structures, home, and for inpatients, 
hospital ward); presumptive source of BSI; patient out-
come at the time of notification; and specimen data 
(date of sampling, pathogen detected, carbapenem-
resistant status, phenotypic or genotypic confirmation 
of carbapenemase production and identification of 
the carbapenemase enzyme). Only section 2 is trans-
ferred to the central level, in order to maintain case 
anonymity.
Data collected at ISS are entered and stored in a dedi-
cated Microsoft Access database.
Statistical analysis
Data analysed and presented here were collected in 
the ISS database up to 18 July 2018 and refer to CPE-
BSI occurring in the period from 1 January 2014 to 31 
December 2017. Cases diagnosed earlier were excluded 
because of low adherence to the new surveillance sys-
tem in 2013 [22]. We also excluded from analysis all 
BSI cases lacking date of diagnosis or indication of 
the microorganism involved or not meeting case defi-
nition (346/7,978, 4.3%). Data were summarised using 
Table 1
Main characteristics of cases of bloodstream infection due 
to carbapenemase-producing Enterobacteriaceae reported 
to the national surveillance system, Italy, 2014–2017 
(n = 7,632)
Characteristics N %
Pathogen
Klebsiella pneumoniae 7,490 98.1
Escherichia coli 142 1.9
Sexa
Female 2,817 37.3
Male 4,731 62.7
Age group (years)a
0–19 101 1.4
20–39 411 5.6
40–59 1,642 22.2
60–79 3,677 49.7
≥ 80 1,569 21.2
Nationality
Italian 7,631 96.4
Other 271 3.6
Patient location at 
symptom onseta
Hospital 6,386 87.2
Otherb 937 12.8
Total 7,632 100
IR: incidence rate.
a For 84 (1.1%) cases, sex was not indicated; for 232 (3.0%) cases, 
age was not reported; for 309 (4.0%) cases, patient location was 
not indicated.
b Home or long-term care facility.
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frequency tables for categorical variables. Incidence 
rates (IR) were calculated at national level for the years 
2014–17 either as number of notifications per 100,000 
hospital patient days (HD) using data from the national 
hospital discharge registry (HDR) [23], or as number of 
notifications per 100,000 inhabitants using the Italian 
population as denominator [24-27]. The previous indi-
cators were also calculated by specific age groups 
(5-year intervals) and by sex. We also calculated age-
standardised [28] IR by calendar year. When calculating 
specific and adjusted IR, cases with unspecified sex 
(1.1%) or age (3.0%) were randomly imputed based on 
the relative sex and age distribution of the other cases.
Data were analysed using Stata, version 13.0 (Stata 
Corporation, College Station, TX, US).
Results
In the period 2014–17, 330 LHUs or hospitals reported 
7,632 CPE-BSI from all Italian regions and autonomous 
provinces. In particular, LHUs or hospitals reporting 
at least one case every year were 153, 196, 211 and 
214 in 2014, 2015, 2016, and 2017, respectively. Most 
of the cases (7,490, 98.1%) were due to  K. pneumo-
niae, while E. coli was reported in only 142 (1.9%) cases. 
Patients were mainly male (62.7%) and more than 70% 
were ≥ 60 years old. Less than 4% of the cases had non-
Italian nationality (Table 1) and of these, more than 
40% were from eastern Europe. Specifically, the larg-
est group of patients with non-Italian nationality were 
from Romania (54/271, 19.9%), Albania (23/271, 8.5%), 
Morocco (17/271, 6.3%) and Ukraine (11/271, 4.1%); the 
remaining cases came from 46 other countries.
For the majority of patients for whom information was 
available, the onset of symptoms occurred in a hos-
pital setting (87.2%); symptoms occurred at home 
(9.9%) or in a long-term care facility (2.9%) for a minor-
ity of patients. When BSI onset occurred in hospital, 
patients were more commonly in intensive care units 
(ICU) (2,430/6,401, 38.0%), in general medicine wards 
(881/6,401, 13.8%) or in surgical wards (725/6,401, 
11.3%). Other wards were reported less frequently, and 
accounted for 36.9% (2,365/6,401) of cases (data not 
shown).
Figure 1  shows the frequency and crude IR (per 
100,000 inhabitants) of CPE-BSI cases distributed by 
month and year of diagnosis. We observed an increase 
in the annual number of reported cases, as well as in 
the IR over the period analysed. The annual number, 
the crude IR and the age-standardised IR in 2014 
were 1,403, 2.31 and 2.10, respectively; in 2017 these 
numbers raised to 2,208, 3.64 and 3.30, respectively. 
Overall, the IR increased significantly during the study 
period (incidence rate ratio (IRR) = 1.16, 95% confidence 
interval (CI): 1.13–1.18); however, the IRs in 2016 and 
2017 were very similar (IRR = 1.01, 95% CI: 0.95–1.07, 
p = 0.67). Similar results were obtained adjusting for 
age and sex.
The CPE-BSI IR among hospitalised patients was 2.97 
per 100,000 HD, with an increasing trend from 2.12 in 
2014 to 3.45 in 2017 (data not shown).
Figure 2 shows the frequency of CPE-BSI cases (panel 
A), the IR per 100,000 inhabitants (panel B) and the IR 
per 100,000 HD (panel C) stratified by age group and 
sex reported in the period 2014–17. We observed that 
the number of cases slightly increased with age until 40 
years, then cases dramatically increased with a peak 
at 65–79 years; cases sharply declined in the oldest 
age groups. The number of cases was always higher 
in males than in females for all age groups (Figure 2, 
panel A).
When considering the IRs per 100,000 inhabitants by 
age group and sex (Figure 2, panel B), we observed 
similar IRs in males and females up to the 35–39 
years age group, higher IRs in males than in females 
Figure 1
(A) Frequency and (B) incidence rate per 100,000 inhabitants by month and year of bloodstream infections due to 
carbapenemase-producing Enterobacteriaceae reported to the national surveillance system, Italy, 2014–2017
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in the older age groups and then a decreasing trend in 
females after the 80–84 years age group.
When considering the specific IR per 100,000 HD (IR-
HD) by age group and sex (Figure 2, panel C) among 
hospitalised patients, we observed that the IR-HD was 
higher among men in each age group compared with 
females with the exception of the 10–14 years age 
group. Overall, the IR-HD did not show a continuous 
increase with age. The highest IR-HD was observed for 
the 50–54 and 55–59 years age groups, with a decreas-
ing trend starting from the 70–74 years age group.
Mostly, the reported source of the CPE-BSI was a central 
or peripheral venous catheter (CVC/PVC) (1,376/5,754, 
23.9%;) or a urinary tract infection (UTI) (1,216/5,754, 
21.1%;). A primary infection was reported in 20.4% 
(1,174/5,754) of cases; less frequently, the source of 
the CPE-BSI was associated with pneumonia (including 
ventilator-associated pneumonia) (926/5,754, 16.1%), 
abdominal infections (731/5,754, 12.7%), non-surgical 
site infections (NSSI) (172/5,754, 3.0%), or surgical site 
infections (SSI) (159/5,754, 2.8%) (data not shown).
When stratifying data on source of CPE-BSI by sex, we 
observed significant differences between males and 
females: origin from NSSI or SSI was significantly more 
frequently reported in females than in males (respec-
tively 3.7% 77/2,101 vs 2.6% 95/3,606, p = 0.03 and 
3.7% 77/2,101 vs 2.3% 82/3,606, p < 0.01). On the other 
hand, origin from UTI or pneumonia was significantly 
more frequently reported in males than in females 
(respectively 22.5% 812/3,606 vs 18.7% 393/2,101, 
p < 0.01 and 17.2% 620/3,606 vs 14.1% 296/2,101, 
p < 0.01).
At the time of reporting, a high percentage of cases 
was still in hospital (5,247/6,869, 76.4%), 6.7% 
(457/6,869) had been discharged, and the remain-
ing 17.0% (1,165/6,869) was reported to have died. 
Mortality was significantly associated with age 
(p < 0.01); in particular, mortality was higher in children 
0–9 years old (5/31, 16.1%) and in the elderly aged ≥ 75 
years (528/2,428, 21.7%). Using univariate analysis, 
women showed a higher mortality compared with men 
(18.1% vs 16.4%, 460/2,538 vs 700/4,269 respectively), 
although this was not statistically significant (p = 0.07). 
When performing a multiple logistic model adjusting 
simultaneously for age and sex, age was still associ-
ated with death significantly (p < 0.01) while there was 
not a significant association with sex (data not shown).
A carbapenemase enzyme identified in the CPE strains 
isolated from BSI was reported in 60.4% (4,612/7,632) 
Figure 2
(A) Frequency, (B) incidence rate per 100,000 inhabitants and (C) incidence rate per 100,000 hospital patient days of 
bloodstream infection cases due to carbapenemase-producing Enterobacteriaceae stratified by age group and sex reported to 
the national surveillance system, Italy, 2014–2017
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of cases only. There was no association with the lack 
of carbapenemase enzyme identification with age 
and sex of the patient and with the year of diagnosis. 
Carbapenemase enzymes were detected mostly by 
phenotypic tests only (3,004/4,612, 65.1%); genotypic 
tests only or both tests were applied in a minority of 
cases (625/4,612 and 983/4,612, 13.6% and 21.3%, 
respectively). However, over the years there was a sig-
nificant increase of the detection of carbapenemase 
enzymes using genotypic tests (from 24.7%, 218/881, 
in 2014 to 45.1%, 596/1,321 in 2017). In most cases the 
enzyme reported was  K. pneumoniae  carbapenemase 
(KPC) (in 95.2% of K. pneumoniae and 81.4% of E. coli). 
Metallo-beta-lactamases (MBL) were reported in 2.1% 
of cases, and carbapenem-hydrolysing oxacillinase-48 
(OXA-48) in 1.2%. Associations between MBL and KPC 
(0.9%) or MBL and OXA-48 (0.3%) were also rarely 
identified. When genotypic tests were applied to iden-
tify the MBL genes, those detected were mainly Verona 
integron-encoded metallo-beta-lactamase (VIM) 
(65/86, 75.6%) followed by New Delhi metallo-beta-
lactamase (NDM) (21/86, 24.4%)(Table 2). NDM was 
reported only in the years 2016–17, mainly in K. pneu-
moniae  (20/21, 95.2%), and often in association with 
OXA-48.
Discussion
During the period under analysis, the CPE-BSI crude 
IR initially increased until 2016 then reached a pla-
teau, suggesting a stable but highly endemic situation. 
These results confirm the strong public health burden 
of CPE infections in Italy, as already indicated by the 
EuSCAPE project, based on sentinel hospitals [15,17], 
or by data from single hospitals/regions [21,29,30].
The results of the countrywide surveillance showed 
a high incidence of CPE-BSI in the Italian population, 
especially in men aged 65 years and older. The micro-
biological results of the surveillance showed predomi-
nance of KPC-producing  K. pneumoniae  and marginal 
presence of other carbapenemase enzymes such as 
MBL, confirming previous findings [8,31].
CPE-BSI cases more often occurred in hospitalised 
patients admitted to ICU or to general medicine wards, 
mainly associated with the presence of invasive 
devices (e.g. CVC/PVC).
The reason for the higher incidence of CPE-BSI in males 
than in females is not clear, but it is in accordance with 
the observation that the incidence of BSI/sepsis by all 
pathogens is higher in males than in females [32]. It is 
of note that in several studies this difference was found 
specifically for BSI/sepsis due to Klebsiella species [33-
35]. Confirmation of this finding can also be obtained 
examining the European Centre for Disease Prevention 
and Control Atlas database, where the higher propor-
tion of carbapenem-resistant  K. pneumoniae  in males 
is particularly evident in countries at high prevalence 
of carbapenem resistance such as Romania and Italy. 
Although there is no clear hypothesis to explain this 
difference, the higher frequency of sepsis in males 
has been associated with a genetic predisposition 
[36]. It is acknowledged that marked differences exist 
between males and females in the incidence of vari-
ous diseases, including infections. Such differences 
may find an explanation in immunological responses, 
in physiological and anatomical differences influencing 
exposure and transmission of microorganisms, or even 
in behavioural factors influencing exposure to microor-
ganisms or access to healthcare [37].
Table 2
Type of carbapenemase enzyme detected in carbapenemase-producing Enterobacteriaceae isolates from bloodstream 
infections reported to the national surveillance system, Italy, 2014–2017
Carbapenemase enzyme
Klebsiella pneumoniae Escherichia coli Total
N % N % N %
KPC 4,323 95.2 57 81.4 4,380 95.0
MBLa 87 1.9 12 17.1 99 2.1
KPC + MBLb 43 0.9 0 0.0 43 0.9
OXA-48 55 1.2 1 1.4 56 1.2
MBLc + OXA-48 15 0.3 0 0.0 15 0.3
KPC + OXA-48 3 0.1 0 0.0 3 0.1
NDd 16 0.4 0 0.0 16 0.3
Not indicated 2,948 – 72 – 3,020 –
Total 7,490 – 142 – 7,632 –
KPC: Klebsiella pneumoniae carbapenemase; MBL: metallo-beta-lactamase; ND: not determined; NDM: New Delhi metallo-beta-lactamase; 
OXA-48: carbapenem-hydrolysing oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.
a Genotyping available for 59 MBLs: 51 VIM (47 in K. pneumoniae; 4 in E. coli) and 8 NDM (7 in K. pneumoniae; 1 in E. coli).
b Genotyping available for 13 MBLs: 11 VIM and 2 NDM (all in K. pneumoniae).
c Genotyping available for 14 MBLs: 3 VIM and 11 NDM (all in K. pneumoniae).
d Not determined (discrepancy between genotypic and phenotypic results).
Percentages were calculated excluding those isolates without enzyme identification.
6 www.eurosurveillance.org
In our study, we observed an increase of CPE-BSI IR as 
age increased. This increase, particularly in patients 
aged 65 years and older, could be related to the higher 
vulnerability of the elderly [38], which could determine 
higher frequency and longer hospital stay compared 
with younger patients. The association with age had 
already been described in another study published in 
2007 on all type of bacteraemia [33].
Considering IR for hospitalised patients only, and 
based on HD, the association with age was less strong. 
In fact, while we confirmed higher IR-HD in males 
than in females, the IR-HD did not show a continuous 
increase with age, being higher in patients aged 50–59 
years and decreasing in those aged 70 years and over. 
The decreasing trend of CPE-BSI in hospitalised elderly 
patients could be related to the admission of these 
patients to wards with less intensive levels of care (e.g. 
long-term care/geriatrics), with a possible lower risk 
of acquiring CPE infections. Unfortunately, data from 
HDR provided by the MoH did not contain details about 
all the ward units to which patients were admitted 
throughout their hospital stay.
The greater number of deaths observed in the extreme 
ages of life could be due to the limited ability of new-
borns to mount an efficient immune response [39] and 
to the poor response of the immune system [38] and 
the presence of comorbidities in elderly patients.
Because most CPE-BSI cases occurred in Italian 
patients, the impact of foreign or migrant populations 
seems to be marginal. However, we were not able to 
calculate IR stratified by nationality to better disentan-
gle the data.
This study has some limitations. We cannot exclude 
the possibility that the increase in CPE-BSI IR over 
the 4-year period could be due at least in part to the 
progressive adherence of the LHUs and the hospitals 
to the surveillance system. Under-reporting is likely 
present, as suggested by differences in the number 
of cases when comparing data from this surveillance 
system with those from other sources such as antibi-
otic resistance surveillance AR-ISS, regional reports or 
scientific publications [22], (Supplement S1). Another 
limitation of this study is that this national surveil-
lance system is based on a broad case definition not 
requiring the detection of carbapenemase production. 
In fact, ca 40% of the CPE-BSI cases reported do not 
contain information about the phenotypic or genotypic 
detection of the resistance mechanism involved, so 
the system cannot recognise isolates with resistance 
mechanisms other than carbapenemase production 
(e.g. reduction of membrane permeability in combina-
tion with overexpression of AmpC enzymes or ESBLs) 
that are included in the CPE surveillance. However, the 
predominance of carbapenemase producing  K. pneu-
moniae  among carbapenem non-susceptible isolates 
reported by previous studies in Italy [8,16] suggests 
that the isolates in which carbapenemase production 
was not specified were mainly CPE. Lastly, the mortal-
ity associated with CPE infection may have been under-
estimated because there was no planned follow up of 
the patients.
The surveillance results show that CPE-BSI represent 
a high burden of serious antibiotic-resistant infections 
and should be considered a threat to patient safety 
in Italy and also in other countries due to the cross-
border mobility of patients [40]. The situation suggests 
there is a need for urgent interventions by the Italian 
health authorities.
To control the spread of CPE infections, the circular let-
ter that instituted the CPE surveillance (MoH DGPRE 
n°4968 26/02/2013) also contained specific recom-
mendations such as application of infection control 
protocols including screening of patients and isolation 
of cases, especially in intensive care and other high-
risk wards. However, the burden of antibiotic-resistant 
infections in Italy remains a serious issue and addi-
tional efforts in infection control should be made. To 
this end, in November 2017 the Italian MoH, in accord-
ance with the regional authorities, issued the first 
strategic Italian plan to fight antimicrobial resistance 
with a one-health approach [41]. Several activities are 
planned over a 3-year period to prevent and control 
antibiotic-resistant infections including a reinforce-
ment of surveillance, prevention and control of health-
care-associated infections, antimicrobial stewardship, 
training, communication campaigns and research.
Within this plan, BSI-CPE surveillance plays a central 
role in monitoring the impact of the implementation of 
the various activities included in the national plan at 
regional and hospital level.
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